- Home
- EWCZ vs SABS Comparison
EWCZ vs SABS Comparison
Compare EWCZ & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | SABS |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.3M | 181.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EWCZ | SABS |
|---|---|---|
| Price | $4.14 | $3.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $5.50 | ★ $9.80 |
| AVG Volume (30 Days) | ★ 341.6K | 298.5K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.45 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $211,264,000.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $1.00 |
| 52 Week High | $7.60 | $6.60 |
Technical Indicators
Market Signals| Indicator | EWCZ | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 49.91 |
| Support Level | $3.38 | $3.56 |
| Resistance Level | $4.06 | $4.19 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 98.76 | 36.60 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.